Treats partial-onset or primary generalized tonic-clonic seizures. ANDA 217443, held by Ascent Pharms Inc. Topiramate.
As of Nov 15, 2026, ANDA 217443 (Topiramate), held by Ascent Pharms Inc, was first approved by FDA on Jan 12, 2026, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Topiramate extended-release capsules are indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older; adjunctive therapy for the treatment of partial-onset, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome (LGS) in patients 6 years of age and older Preventive treatment of migraine in patients 12 years of age and older 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 12, 2026 | Original application | Approved | None posted |
| Topiramate25MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate50MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate100MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate200MG · capsule, extended release;oral | Topiramate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters